PharmatrophiX Selected for Landmark UCSF-led platform trial in rare neurodegenerative disease; Unveils New Data at Tau Global Conference
- Posted on May 14, 2026
PharmatrophiX unveiled preclinical data at the Global Tau Conference further supporting evidence that LM11A-31 is a multi-action shield for the brain's connections... Read More
Targeting Upstream Neurodegeneration: LM11A-31 in Alzheimer’s Disease and PSP
- Posted on May 7, 2026
David Setboun, Pharm.D., MBA, CEO of PharmatrophiX, and Frank M. Longo, MD, PhD, Co-founder & Chairman, discuss LM11A-31’s upstream mechanism targeting p75 signaling and its potential to modify neurodegenerative disease biology.... Read More